Guess which ASX 200 healthcare share just rocketed 11% on 'groundbreaking trial'

Up 67% in a year, investors are sending the ASX 200 healthcare share soaring again today.

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) is up a very healthy 0.8% today, but this ASX 200  healthcare share is leaving those gains wanting.

Shares in the biopharmaceutical company closed on Wednesday trading for $20.71.

The stock then entered a trading halt pending an announcement on the results of its phase 2 clinical trial for one of its drug candidates intended to treat patients with Pitt Hopkins syndrome.

The ASX 200 healthcare share exited that trading halt this morning following on that announcement, which saw shares leap to $23.07 apiece, up 11.4%.

After some likely profit-taking, shares are currently changing hands for $22.67 apiece, up 9.5%.

Any guesses?

If you said Neuren Pharmaceuticals Ltd (ASX: NEU), go to the front of the virtual class.

Here's what's spurring investor interest on Monday.

ASX 200 healthcare share soars on significant results improvements

The Neuren Pharmaceuticals share price is leaping higher today after the company reported on the top-line results from its phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS).

PTHS can be severely debilitating for patients, yet there are currently no approved treatments for the disease.

And investors are bidding up the ASX 200 healthcare share after Neuren Pharmaceuticals noted a "statistically significant improvement" was observed relative to the baseline following treatment. That improvement was observed by both caregivers and clinicians across all four efficacy measures designed to assess the core characteristics of PTHS.

Patients showed improvements in areas including communication, social interaction, cognition and motor abilities.

Nine out of 11 children assessed by clinicians showed improvement, while eight out of 11 children assessed by caregivers showed improvement.

NNZ-2591 was also reported to be safe and well tolerated, with no serious or severe adverse events during the phase 2 trial.

Commenting on the clinical trial results sending the ASX 200 healthcare share soaring today, Neuren Pharmaceuticals CEO Jon Pilcher said:

We are very excited about the results of this first clinical trial in Pitt Hopkins patients. This underserved community has such urgent unmet need, and we can now continue towards our goal of developing a first approved treatment.

We are very grateful to the people in the Pitt Hopkins community and at the trial sites in the United States who enabled the successful completion of this extremely challenging, but groundbreaking trial.

Nancy Jones, Neuren vice president of Clinical Development added:

The consistent results on the PTHS specific assessments affirm the need for syndrome specific measurements in severe neurodevelopmental disorders where measures that were developed for broader populations may not be as appropriate.

Neuren Pharmaceuticals share price snapshot

With today's intraday gains factored in, the ASX 200 healthcare share is up an impressive 67% since this time last year.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

a man in a business suit sits at his laptop computer at his desk and smiles broadly in an office setting, giving an air of optimism and confidence.
Share Gainers

Why these three ASX All Ords stocks are leading the charge higher this week

These three ASX All Ords shares rocketed higher this week. But how?

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Share Gainers

Why Botanix, Strike Energy, Talga, and West African Resources shares are pushing higher

These shares are ending the week on a high. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!

The little-known ASX healthcare stock has delivered eye-watering 12-month gains. But how?

Read more »

A young bearded man wearing a white t-shirt with a yellow backdrop holds up his arms to his chest and points to the camera in celebration of ASX shares rising today
Share Gainers

Why Bigtincan, DroneShield, Guzman Y Gomez, and Helia shares are racing higher

These shares are having strong sessions on Thursday. But why?

Read more »

Three girls compete in a race, running fast around an athletic track.
Share Gainers

Here's why ASX uranium shares like Deep Yellow are running hot today

ASX uranium stocks are on fire this Wednesday.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Chrysos, Hansen Technologies, Pantoro, and WA1 Resources shares are pushing higher

These shares are having a good time on hump day. But why?

Read more »

piggy bank at end of winding road
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors enjoyed a lucrative Tuesday session today.

Read more »

A man sees some good news on his phone and gives a little cheer.
Share Gainers

Why Capitol Health, Infratil, Newmont, and Race Oncology shares are charging higher

These shares are having a good session. But why?

Read more »